Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...

The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...

In an interview with Stephen Onikoro, chief operating officer of PharmaForceIQ, he shared that pharma marketers can’t pour ...

Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious ...

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after ...

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A ...

After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI ...